Prostate Adenocarcinoma malady

Wikipedia: Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive...⁴⁴ more...

MalaCards: Prostate Adenocarcinoma, also known as adenocarcinoma of prostate (disorder), is related to gastric adenocarcinoma and squamous cell carcinoma. An important gene associated with Prostate Adenocarcinoma is CTNND2 (catenin (cadherin-associated protein), delta 2), and among its related pathways are JNK Pathway and ILK Signaling. The drugs mitomycin and thiotepa and the compounds cyclic amp and forskolin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, lymph node and brain, and related mouse phenotypes are embryogenesis and growth/size.

Aliases & Descriptions:

prostate adenocarcinoma 6 7 adenocarcinoma of prostate (disorder) 6

adenocarcinoma of prostate 43 adenocarcinoma 43

Diseases related to prostate adenocarcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1046)

id	Related Disease	Score	Top Affiliating Genes
1	gastric adenocarcinoma	36.5	MYC, BIRC5, CLDN4, CLDN7, CLDN3, BCL2
2	squamous cell carcinoma	36.0	LGALS1, LGALS3, CD44, CDH1, MKI67, GSTP1
3	barrett's esophagus	35.0	MKI67, GSTP1, CCND1, AMACR, TP53, PTGS2
4	prostatitis	34.3	PI16, PIK3CG, PIM1, WDR19, RELA, PCNA
5	lung adenocarcinoma	34.3	PIK3CG, RB1, BRAF, VEGFA, BMP6, RARB
6	adenocarcinoma	34.2	PI16, PIK3CG, PIM1, WDR19, RELA, PCNA
7	nephrogenic adenoma	33.0	MUC1, AMACR, TP63, KRT7, KLK3, ACPP
8	clear cell adenocarcinoma	32.5	RB1, VEGFA, BIRC5, CDH1, MET, IFI27
9	polymorphous low-grade adenocarcinoma	32.4	PCNA, VIM, LGALS3, MUC1, S100A1, CEACAM3
10	colon adenocarcinoma	32.3	VEGFA, MYC, BMP6, RARB, BIRC5, BCL2
11	cervical adenocarcinoma	32.1	PCNA, BRAF, MYC, CFLAR, CDKN1B, CD44
12	neuroendocrine carcinoma	31.9	SCG2, CHKA, CHGA, MUC1, FSCN1, CDH1
13	papillary adenocarcinoma	31.9	PCNA, VIM, MYC, MUC1, CDH1, ERBB2
14	breast adenocarcinoma	31.7	PCNA, RB1, VEGFA, BMP6, BCL2, BAX
15	adenocarcinoma in situ	31.7	VIM, IFI27, WT1, KRT20, KRAS, PGR
16	endocervicitis	31.6	VIM, MYC, BMP2, BCL2, MUC1, CEACAM3
17	tubular adenocarcinoma	31.5	CHGA, MUC1, CDH1, ENO2, ERBB2, TP63
18	endometrial adenocarcinoma	31.2	PCNA, RB1, VIM, BRAF, VEGFA, MYC
19	esophagus adenocarcinoma	31.2	BCL2, MKI67, CCND1, TP53, PTGS2, EGFR
20	gastric cardia adenocarcinoma	31.1	MYC, MMP2, MET, PTGS2, TGFB1, HGF
21	gallbladder adenocarcinoma	30.9	BRAF, MYC, CHGA, MUC1, BAX, MAPK1
22	papillary serous adenocarcinoma	30.8	ERBB2, KRT7, KRT20, NKX2-1, PGR
23	adenosquamous carcinoma	30.8	CHGA, MUC1, AR, GRP, TP63, PTHLH
24	barrett's adenocarcinoma	30.7	PCNA, BRAF, VEGFA, MYC, BIRC5, S100A2
25	adenoid cystic carcinoma	30.7	PCNA, VIM, LGALS3, MUC1, S100A1, CEACAM3
26	prostate cancer	30.6	AR, GSTP1, PTEN, KLK3, ACPP, TGIF1
27	pancreatic ductal adenocarcinoma	30.6	PIM1, SERPINH1, VIM, BRAF, VEGFA, MYC
28	bronchiolo-alveolar adenocarcinoma	30.6	CDH1, KRT7, KRT20, KRAS, EGFR, NKX2-1
29	ovarian mucinous adenocarcinoma	30.5	UPK3A, AMACR, TP53, KRT7, KRT20, SLC45A3
30	ovarian clear cell adenocarcinoma	30.5	VEGFA, CDH1, MET, ESR2, ERBB2, TP53
31	epididymitis	30.1	CLDN2, CLDN4, CLDN7, CLDN3, AR, GSTP1
32	pancreatitis	30.0	PIK3CG, PIM1, RELA, PCNA, RB1, SERPINH1
33	ovarian cancer	29.4	CEACAM3, FSCN1, FASN, ALPP, ERBB2, KRT7
34	prostatic hypertrophy	29.4	PCNA, AR, GSTP1, FGF2, IGFBP3, IGF1
35	adenomatoid tumor	29.3	VIM, MUC1, MMP2, WT1, KRT7, KRT5
36	hypercalcemia	29.1	VIM, BMP6, CHGA, FGF2, IL2, CCND1
37	neuroendocrine tumor	29.1	RAF1, SCG2, CHGB, CHGA, CEACAM3, MKI67
38	urethritis	29.1	CHGA, CEACAM3, CDH1, ALPP, CALCA, PTGS2
39	merkel cell carcinoma	29.0	KDR, CHGA, MUC1, ENO2, MAPK10, TNC
40	aggressive digital papillary adenocarcinoma	29.0	PCNA, VIM, BIRC5, LGALS3, CHGA, MUC1
41	esophagitis	28.9	PIK3CG, PIM1, RELA, PCNA, RB1, SERPINH1
42	anaplastic carcinoma	28.9	VIM, BRAF, LGALS1, LGALS3, MUC1, S100A4
43	malignant pleural mesothelioma	28.7	BIRC5, BCL2L1, MUC1, CEACAM3, MET, SPP1
44	periampullary adenocarcinoma	28.7	VEGFA, BAX, CDKN1B, CCND1
45	cervical endometrioid adenocarcinoma	28.6	BRAF, BCL2, CHGA, MUC1, CEACAM3, CDH1
46	carcinoid tumors	28.4	PCNA, RAF1, CLDN2, CLDN4, CLDN3, KDR
47	hodgkin's lymphoma	28.2	PIK3CG, BCL2, BCL2L1, LGALS1, CFLAR, ATM
48	pleomorphic adenoma	28.2	PCNA, VIM, BMP2, MUC1, S100A1, CDKN1B
49	breast cancer	28.2	VEGFA, KDR, BCL2, ATM, MMP2, AR
50	teratoma	28.1	PCNA, VIM, BCL2, BAX, JUN, CDH1

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 mitomycin, thiotepa

MalaCards organs/tissues related to prostate adenocarcinoma:

²²

MGI Mouse Phenotypes related to prostate adenocarcinoma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	embryogenesis phenotype	MP:0005380	INF	WDR19, VIM, BRAF, MYC, RARB, RAF1
2	growth/size phenotype	MP:0005378	INF	PIK3CG, PIM1, RELA, RB1, BRAF, MYC
3	normal phenotype	MP:0002873	INF	RELA, BRAF, VEGFA, MYC, ,
4	hearing/vestibular/ear phenotype	MP:0005377	INF	WDR19, RB1, MYC, , , RARB
5	adipose tissue phenotype	MP:0005375	INF	RB1, BRAF, MYC, BCL2, AZGP1, CDKN1B
6	no phenotypic analysis	MP:0003012	INF	PCNA, RB1, VEGFA, MYC, MUC1, ATM
7	endocrine/exocrine gland phenotype	MP:0005379	INF	ZFX, MSMB, CDKN1B, ARID4A, FGF10, FGFR1
8	hematopoietic system phenotype	MP:0005397	INF	PIM1, PCNA, BRAF, CLDN7, ZFX, BCL2
9	integument phenotype	MP:0010771	INF	PIK3CG, RELA, RB1, BRAF, MYC, RAF1
10	craniofacial phenotype	MP:0005382	INF	WDR19, MLL, FGF10, FGFR2, ,
11	renal/urinary system phenotype	MP:0005367	INF	BRAF, , RARB, CLDN7, BCL2, UPK3A
12	vision/eye phenotype	MP:0005391	INF	WDR19, RELA, RB1, VIM, BRAF, VEGFA
13	respiratory system phenotype	MP:0005388	10.4	ARID4A, CARM1, CALCA, TP63, DICER1, CRH
14	digestive/alimentary phenotype	MP:0005381	INF	WDR19, RB1, BRAF, VEGFA, MYC,
15	reproductive system phenotype	MP:0005389	INF	VEGFA, , , RARB, ZFX, FYN
16	muscle phenotype	MP:0005369	INF	PIK3CG, WDR19, RELA, RB1, VIM, BRAF
17	behavior/neurological phenotype	MP:0005386	INF	RB1, VIM, BRAF, RARB, KDR, LGALS1
18	tumorigenesis	MP:0002006	INF	RB1, BRAF, MYC, BCL2, , MUC1
19	immune system phenotype	MP:0005387	INF	VIM, BRAF, RAF1, ZFX, KDR, LGALS1
20	cardiovascular system phenotype	MP:0005385	INF	PIK3CG, RELA, RB1, VIM, BRAF, VEGFA
21	liver/biliary system phenotype	MP:0005370	INF	VEGFA, SCD, , MLL, ARID4A, AR
22	nervous system phenotype	MP:0003631	INF	WDR19, RELA, RB1, SERPINH1, BRAF, MYC
23	cellular phenotype	MP:0005384	INF	PIK3CG, PIM1, WDR19, RELA, PCNA, RB1
24	homeostasis/metabolism phenotype	MP:0005376	INF	PIK3CG, RELA, RB1, VIM, BRAF, VEGFA
25	limbs/digits/tail phenotype	MP:0005371	INF	WDR19, RELA, RB1, VEGFA, ,
26	mortality/aging	MP:0010768	INF	WDR19, RELA, RB1, SERPINH1, BRAF, VEGFA
27	pigmentation phenotype	MP:0001186	INF	RB1, BRAF, MYC, , BCL2, CDKN1B
28	skeleton phenotype	MP:0005390	INF	PIK3CG, WDR19, RELA, RB1, BRAF, VEGFA
29	other phenotype	MP:0005395	INF	SERPINH1, RARB, KDR, ITGB1, ARID4A, IL2

Articles related to prostate adenocarcinoma:

(show top 50)    (show all 303)

id	Title	Authors	Year	Affiliating Genes
1	IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. (21304397)	Ambrosini-Spaltro A.... Foschini M.P.	2011	IGFBP2
2	Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. (20348237)	Breuninger S.... Hofmann I.	2010	PKP3, PKP1
3	Synthesis and antitumor properties of selenocoxib-1 a gainst rat prostate adenocarcinoma cells. (19918950)	Desai D.... Sinha R.	2010	PTGS2
4	PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. (19395652)	Blando J.... Walker C.L.	2009	PTEN, PIK3CG
5	Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. (19479935)	Whelan J.T.... Bertrand F.E.	2009	PTEN, NOTCH1
6	Evidence of heavy methylation in the galectin 3 promo ter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. (19701499)	Ahmed H.... Vasta G.R.	2009	LGALS3, LGALS1
7	Epidemiologic profile and prognostic factors in clin ically localized prostate adenocarcinoma submitted to surgical treatment (20076923)	Nassif A.E.... Pozzobon H.J.	2009	KLK3
8	BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. (19079609)	Jeong J.H.... Chin L.	2008	BRAF, MAPK10
9	Cytokeratin (AE1/AE3) in addition to alpha-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma. (18206500)	Raspollini M.R.	2008	TP63
10	Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats. (18058807)	Powolny A.A.... Clinton S.K.	2008	IGF1, VEGFA
11	Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. (17804708)	Mehra R.... Shah R.B.	2007	TMPRSS2, ETV1
12	Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. (17671224)	Liao C.P.... Roy-Burman P.	2007	PTEN
13	Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. (17963516)	Yin M.... Parwani A.V.	2007	KLK3, SLC45A3
14	Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. (17448023)	Mhawech-Fauceglia P.... Penetrante R.	2007	FOLH1
15	Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. (17134736)	Sung M.T.... Cheng L.	2007	TP63, AMACR
16	Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. (17378849)	Mohamed M.A.... Hamilton P.W.	2007	SMARCA5
17	Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. (16564913)	Shah U.S.... Pflug B.R.	2006	FASN
18	A molecular correlate to the Gleason grading system for prostate adenocarcinoma. (16829574)	True L.... Nelson P.S.	2006	MAOA
19	Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. (16652121)	Tomas D.... Kruslin B.	2006	TNC
20	Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. (16607376)	Hameed O.... Humphrey P.A.	2006	AMACR
21	Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma. (16616377)	Langat D.K.... Hunt J.S.	2006	HLA-G
22	Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). (15867270)	Mentor-Marcel R.... Elgavish A.	2005	SPP1
23	Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia. (16324197)	Patton K.T.... Yang X.J.	2005	ANXA1
24	15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. (15850718)	Vang K.... Ziboh V.A.	2005	ALOX15
25	Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. (16230178)	Theodoropoulos V.E.... Ghikonti I.	2005	CHGA
26	Urothelial carcinoma of the urinary bladder with a component of acinar/tubular type differentiation simulating prostatic adenocarcinoma. (15188146)	Huang Q.... Weiss L.M.	2004	ACPP, THBD
27	Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. (15517916)	Effert P.... Jakse G.	2004	SLC2A1
28	Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. (14968443)	Sciarra A.... Silverio F.D.	2004	KLK3, CHGA
29	Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. (15166661)	Skinnider B.F.... Amin M.B.	2004	KLK3, AMACR
30	Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma. (12647777)	Sciarra A.... Di Silverio F.	2003	CHGA
31	Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. (14532978)	Karan D.... Batra S.K.	2003	ADAM10, ADAM17, ADAM9
32	Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4. (12837460)	Wang M.H.... Young C.Y.	2003	AR, C1orf116
33	Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. (12454820)	Mhawech P.... Pelte M.F.	2002	ACPP, UPK3A
34	15-lipoxygenase-1 overexpression in prostate adenocarcinoma. (12664577)	Kelavkar U.... Badr K.	2002	ALOX15
35	Extensive bone metastases in a patient with prostatic adenocarcinoma and normal serum prostate-specific antigen and prostatic acid phosphatase. (11595863)	Yuksel M.... Berkarda S.	2001	ACPP
36	Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score. (11500787)	Hering F.L.... Srougi M.	2001	BCL2
37	Immunohistochemical study of the receptors for retino ic acid in prostatic adenocarcinoma. (11268473)	Kikugawa T.... Yokoyama M.	2000	RARB, RARS
38	Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. (10580834)	Goossens K.... Verhoeven G.	1999	IGFBP3, IGFBP2
39	Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma. (10022731)	Myers R.B.... Grizzle W.E.	1999	MKI67, IFI27
40	Apoptosis in prostatic adenocarcinomas; a study of relationship to Ki-67 and Bcl-2 protein expression. (9615774)	Tanji N.... Terada N.	1998	BCL2
41	The use of nested RT-PCR of prostate-specific membrane antigen in blood cells: implications for the detection of haematogenous neoplastic cells in patients with prostate adenocarcinoma. (9843660)	Lucotte G.... Burckel A.	1998	FOLH1
42	Isolation and characterization of propagable cell lines (HUNC) from the androgen-sensitive Dunning R3327H rat prostatic adenocarcinoma. (9600341)	Presnell S.C.... Smith G.J.	1998	AR, TF, ACPP
43	5-Azacytidine modulates gamma-glutamyltransferase and glutathione levels in two human prostatic adenocarcinoma cell lines. (9801800)	el yaagoubi M.... Wellman M.	1998	GGT1
44	Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. (9465942)	Pruneri G.... Buffa R.	1998	CHGA, CHGB, SCG2
45	Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. (8602398)	van der Kwast T.H.... Labrie F.	1996	AR
46	Sequence and expression of bone morphogenetic protein 3 mRNA in prolonged cultures of fetal rat calvarial osteoblasts and in rat prostate adenocarcinoma PA III cells. (7880444)	Chen D.... Harris S.E.	1995	BMP3
47	Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. (8822116)	Montironi R.... Biagini G.	1995	MMP2
48	Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP. (7527352)	Swinnen J.V.... Verhoeven G.	1994	DBI
49	Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. (7685237)	Aprikian A.G.... Reuter V.E.	1993	CHGA
50	Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. (1712248)	Young C.Y.... Tindall D.J.	1991	KLK3

Genes related to prostate adenocarcinoma according to GeneCards:

(show top 50)    (show all 225)

id	Symbol	Description	Score	GeneCards Section Context
1	CTNND2	catenin (cadherin-associated protein), delta 2	11.1	Summaries
2	PPAP2A	phosphatidic acid phosphatase type 2A	11.1	Publications, Summaries
3	PART1	prostate androgen-regulated transcript 1 (non-protein coding)	11.0	Summaries
4	ACPP	acid phosphatase, prostate	11.0	Publications
5	AMACR	alpha-methylacyl-CoA racemase	11.0	Publications
6	KLK3	kallikrein-related peptidase 3	11.0	Publications
7	RLN1	relaxin 1	11.0	Publications
8	ALOX15B	arachidonate 15-lipoxygenase, type B	11.0	Publications
9	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
10	CLDN3	claudin 3	11.0	Publications
11	CHGB	chromogranin B (secretogranin 1)	11.0	Publications
12	MSMB	microseminoprotein, beta-	11.0	Publications
13	HPN	hepsin	11.0	Publications
14	SPINT1	serine peptidase inhibitor, Kunitz type 1	11.0	Publications
15	SCG2	secretogranin II	11.0	Publications
16	FOLH1	folate hydrolase (prostate-specific membrane antigen) 1	11.0	Publications
17	CSTA	cystatin A (stefin A)	11.0	Publications
18	IBSP	integrin-binding sialoprotein	11.0	Publications
19	KRT20	keratin 20	11.0	Publications
20	CEACAM3	carcinoembryonic antigen-related cell adhesion molecule 3	11.0	Publications
21	BMP3	bone morphogenetic protein 3	11.0	Publications
22	KRT7	keratin 7	11.0	Publications
23	ST14	suppression of tumorigenicity 14 (colon carcinoma)	11.0	Publications
24	ENO2	enolase 2 (gamma, neuronal)	11.0	Publications
25	IFI27	interferon, alpha-inducible protein 27	11.0	Publications
26	IGFBP2	insulin-like growth factor binding protein 2, 36kDa	11.0	Publications
27	LGALS1	lectin, galactoside-binding, soluble, 1	11.0	Publications
28	CTNND1	catenin (cadherin-associated protein), delta 1	11.0	Publications
29	PROS1	protein S (alpha)	11.0	Publications
30	NGFR	nerve growth factor receptor	11.0	Publications
31	NKX2-1	NK2 homeobox 1	11.0	Publications
32	SYP	synaptophysin	11.0	Publications
33	STMN1	stathmin 1	11.0	Publications
34	ANXA1	annexin A1	11.0	Publications
35	SCD	stearoyl-CoA desaturase (delta-9-desaturase)	11.0	Publications
36	ENG	endoglin	11.0	Publications
37	S100A4	S100 calcium binding protein A4	11.0	Publications
38	RARS	arginyl-tRNA synthetase	11.0	Publications
39	EDNRB	endothelin receptor type B	11.0	Publications
40	MIF	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	11.0	Publications
41	CTNNA1	catenin (cadherin-associated protein), alpha 1, 102kDa	11.0	Publications
42	EDNRA	endothelin receptor type A	11.0	Publications
43	GSTP1	glutathione S-transferase pi 1	11.0	Publications
44	LGALS3	lectin, galactoside-binding, soluble, 3	11.0	Publications
45	FGFR1	fibroblast growth factor receptor 1	11.0	Publications
46	NTRK1	neurotrophic tyrosine kinase, receptor, type 1	11.0	Publications
47	PCNA	proliferating cell nuclear antigen	11.0	Publications
48	RARB	retinoic acid receptor, beta	11.0	Publications
49	AR	androgen receptor	11.0	Publications
50	PTGS1	prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	11.0	Publications

Pathways related to prostate adenocarcinoma according to GeneDecks:

(show top 50)    (show all 264)

id	Pathway	Score	Top Affiliating Genes
1	JNK Pathway36	INF	, BMP3, BMP6, , RAF1, KDR
2	ILK Signaling36	INF	VIM, , BMP3, , KDR, JUN
3	Activation of PKC through GPCR36	INF	, BMP3, BMP6, , RAF1, KDR
4	Development_VEGF signaling via VEGFR2 - generic cascades41	INF	RELA, VEGFA, RAF1, FYN, JUN,
5	TGF-Beta Pathway36	INF	, BMP3, BMP6, , KDR, BCL2
6	Development_EGFR signaling pathway41	INF	MYC, RAF1, JUN, MMP2, ,
7	Activation of PKA through GPCR36	INF	BRAF, , BMP3, BMP6, , RAF1
8	TGF-beta Signaling Pathways37	INF	PIK3CG, RELA, BRAF, MYC, RAF1, JUN
9	Akt Signaling36	INF	PIK3CG, , BMP3, , RAF1, ITGA2B
10	ErbB signaling pathway20	INF	PIK3CG, BRAF, MYC, RAF1, JUN, CDKN1B
11	Mitochondrial Apoptosis36	INF	, BMP3, BMP6, , KDR, BCL2
12	Tec Kinases Signaling36	INF	, BMP3, BMP6, , BCL2, BAX
13	p53 Mediated Apoptosis36	INF	, BMP3, BMP6, , KDR, BCL2
14	Colorectal cancer20	INF	PIK3CG, BRAF, , , TGFB1, TGFBR2
15	Cellular Apoptosis Pathway36	INF	, BMP3, BMP6, , KDR, BCL2
16	Antioxidant Action of Vitamin-C36	INF	, BMP3, BMP6, , KDR, BCL2
17	Glioma Invasiveness36	INF	, BMP3, BMP6, , CD44, ITGA2B
18	GSK3 Signaling36	INF	, BMP3, BMP6, , KDR, CDH1
19	ERK Signaling36	INF	BRAF, MYC, , BMP3, BMP6,
20	Actin-Based Motility by Rho Family GTPases36	INF	BMP3, , ITGA2B, , FGF10, IL2
21	Rac1 Pathway36	INF	BMP3, BMP6, , RAF1, KDR, JUN
22	Estrogen Pathway36	INF	BRAF, , BMP3, BMP6, , RAF1
23	Nanog in Mammalian ESC Pluripotency36	INF	BRAF, , BMP3, BMP6, , RAF1
24	CREB Pathway36	INF	, BMP3, BMP6, , KDR,
25	Breast Cancer Regulation by Stathmin136	INF	, BMP3, , RAF1, FGF10, FGF2
26	EGFR Inhibitor Pathway, Pharmacodynamics34	10.7	KRAS
27	Bladder cancer20	6.8	RB1, BRAF, VEGFA, MYC, RAF1, CDH1
28	Renin-Angiotensin Pathway36	INF	, BMP3, BMP6, , RAF1, KDR
29	NFAT in Immune Response36	INF	, BMP3, BMP6, , KDR, FYN
30	14-3-3 Induced Intracellular Signaling36	INF	, BMP3, , RAF1, JUN,
31	Development_IGF-1 receptor signaling41	INF	RELA, MYC, RAF1, , MAPK1,
32	Rho Family GTPases36	INF	VIM, , BMP3, BMP6, , RAF1
33	PTEN Pathway36	INF	BRAF, , BMP3, , KDR, ITGA2B
34	GPCR Pathway36	INF	BRAF, , BMP3, BMP6, , RAF1
35	Apoptosis and survival_Role of CDK5 in neuronal death and survival41	INF	RAF1, BCL2, BAX, JUN, MAPK10, MAPK1
36	Endothelin-1 Signaling Pathway36	INF	BRAF, MYC, , BMP3, BMP6,
37	Development IGF-RI signaling10	INF	RELA, MYC, RAF1, , MAPK1,
38	MAPK Family Pathway36	INF	BRAF, , BMP3, BMP6, , RAF1
39	Endometrial cancer20	INF	PIK3CG, BRAF, MYC, RAF1, CDH1,
40	Non-small cell lung cancer20	INF	PIK3CG, RB1, BRAF, RAF1, MAPK1,
41	Ras Pathway36	INF	BRAF, , BMP3, , RAF1, KDR
42	mTOR Pathway36	INF	, BMP3, BMP6, , , INS
43	Pathways in cancer20	INF	PIK3CG, RELA, RB1, VEGFA, MYC,
44	NF-KappaB (p50-p65) Pathway36	INF	RELA, , BMP3, BMP6, , KDR
45	ERK5 Signaling36	INF	MYC, , BMP3, BMP6, , KDR
46	NF-KappaB Family Pathway36	INF	RELA, , BMP3, BMP6, , KDR
47	Angiogenesis3	INF	KDR, ITGB1, MMP2, , FGF2, FGFR1
48	Epithelial Adherens Junctions36	INF	, BMP3, BMP6, , CDH1,
49	Phospholipase-C Pathway36	INF	, BMP3, BMP6, , RAF1, KDR
50	Apoptotic Pathways in Synovial Fibroblasts36	INF	, BMP3, BMP6, , KDR,

Compounds related to prostate adenocarcinoma according to GeneDecks:

(show top 50)    (show all 474)

id	Compound	Score	Top Affiliating Genes
1	cyclic amp32 18	INF	RB1, BRAF, RARS, RARB, SCG2,
2	forskolin32 42 9 9	INF	VIM, BRAF, , BMP6, RARS, RARB
3	gnrh32	INF	VIM, RAF1, SCG2, MKI67, AR, INS
4	ndga32	INF	JUN, , FASN, MAPK10, , ALOX5
5	leucine32	INF	RB1, VIM, MYC, RARS, ATM, JUN
6	adriamycin32	INF	RB1, VIM, MYC, BIRC5, BCL2,
7	gemcitabine32 34 9 9	INF	PCNA, VEGFA, MYC, BIRC5, KDR, BCL2
8	deoxyribonucleic acid32	INF	PCNA, , , ZFY, ATM, FGFR2
9	ciglitazone32	INF	RARB, , BAX, JUN, CDKN1B, MMP2
10	irinotecan32 34 9 9	INF	BRAF, VEGFA, , BAX, , CEACAM3
11	cytarabine32 34 9 9	INF	PCNA, RB1, VIM, MYC, BCL2,
12	anisomycin32 42 9 9	INF	PIK3CG, MYC, RAF1, , JUN,
13	folate32	INF	VIM, MYC, KDR, MUC1, CDH1, MMP2
14	polysaccharide32	INF	, BMP6, KDR, LGALS1, LGALS3, FOLH1
15	vitamin d32	INF	VIM, , BMP6, , RARS, RARB
16	troglitazone32 42 9 9	INF	PIK3CG, RB1, BMP6, BIRC5, BCL2, SCD
17	bromodeoxyuridine32	INF	PCNA, RB1, VIM, MYC, BMP6,
18	okadaic acid32 42	INF	RELA, RB1, VIM, MYC, BMP6, RAF1
19	paclitaxel32 34 9 9	INF	PIK3CG, PCNA, RB1, VIM, BRAF, VEGFA
20	ascorbic acid32 18	INF	PIK3CG, PCNA, SERPINH1, , , RAF1
21	egcg32	INF	PIK3CG, RAF1, , FASN, MAPK10, IGFBP3
22	sodium nitroprusside32	10.4	PCNA, BMP6, CAT, PTGS1, SST, CRH
23	vincristine32 34 9 9	13.4	MLL, FGF2, HSF1, CALCA, PTHLH, RPSA
24	dmso32	10.2	VIM, BMP6, CHGA, ALOX5, ALPP, GNRH1
25	sp 60012532 42	10.9	PIK3CG, CASP3, TP53
26	trastuzumab32 34 9 9	10.8	PIK3CG, RAF1, BIRC5, KDR, MUC1, CDKN1B
27	nitric oxide32 9 18 9	INF	RB1, SERPINH1, , BMP6, BIRC5, KDR
28	resveratrol32 9 18 9	INF	PIK3CG, PCNA, RB1, VEGFA, , RAF1
29	lactacystin32	INF	PIK3CG, MYC, RAF1, BIRC5, BCL2,
30	imatinib32 34 9 9	INF	PIK3CG, BRAF, VEGFA, MYC, BMP6, RAF1
31	adpribose32	INF	PIK3CG, PCNA, RB1, BIRC5, , BAX
32	pdtc32	INF	PIK3CG, RAF1, BIRC5, BCL2, ,
33	dihydrotestosterone32 9 18 9	INF	VIM, , BMP6, , FOLH1,
34	glutamine32	INF	PIK3CG, PCNA, VIM, BMP6, RAF1, LGALS1
35	cytochalasin d32 42	INF	PIK3CG, VIM, RAF1, CD44, CDH1, MMP2
36	paraffin32	INF	RELA, PCNA, RB1, VIM, BRAF, VEGFA
37	indomethacin32 9 9	INF	PCNA, VIM, MYC, , BMP6, RAF1
38	tamoxifen32 34 9 9	INF	PCNA, VIM, VEGFA, MYC, BMP6, RAF1
39	progestins32	INF	MKI67, AR, FASN, CCND1, IGFBP2, IGFBP3
40	5-hydroxytryptamine32	INF	VIM, BMP6, RAF1, SCG2, CHGA, FYN
41	calcitriol32 42 9 18 9	INF	RB1, MYC, , BMP3, BMP6,
42	hyaluronic acid32 18	INF	VIM, MYC, BMP6, MUC1, CD44, CDH1
43	phosphotyrosine32	INF	PIK3CG, RAF1, KDR, LGALS1, FYN, CDH1
44	thymidylate32	INF	PCNA, RB1, VIM, VEGFA, BIRC5, BCL2
45	calcium32 9 18 9	INF	PIM1, RELA, RB1, BRAF, , BMP3
46	cysteine32	INF	PCNA, RARB, RAF1, KDR, , SCG2
47	atp32	INF	PIM1, RB1, SERPINH1, BRAF, BIRC5,
48	cholesterol32 9 18 9	INF	RB1, , BIRC5, CLDN3, SCD,
49	oxaliplatin32 34 9 9	INF	VEGFA, BIRC5, , , GSTP1, FAS
50	thyroxine32 18	INF	PCNA, , CEACAM3, , INS, FGF2

Cellular components related to prostate adenocarcinoma according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	cell surface	GO:009986	INF	VEGFA, , LGALS1, CD44, CDH1, ITGB1
2	integral to plasma membrane	GO:005887	INF	EDNRA, NGFR, NRG1, PPAP2A, NTRK1, CTLA4
3	plasma membrane	GO:005886	INF	NFKBIA, PDPK1, KRAS, NDRG1, C1orf116, EDNRA
4	nucleoplasm	GO:005654	INF	NGFR, NOTCH1, SMARCA5, NR1H2, PPARA, PPARG
5	extracellular space	GO:005615	INF	, SOD1, NPY, PECAM1, ADAM9, HGF
6	cytosol	GO:005829	INF	CTNNA1, CTNNB1, CTNND1, PPARG, NQO1, RPS6KB1
7	cytoplasm	GO:005737	INF	NR1H2, KRT18, KRT20, SH3GLB2, NDRG1, C1orf116
8	extracellular region	GO:005576	INF	AZGP1, ANXA1, IGFBP5, IGFBP2, IGFBP3, IGF1
9	nucleus	GO:005634	INF	HSPB1, ERG, TP53, TP63, PTEN, PTGS2
10	protein complex	GO:043234	INF	SYP, PTGS2, TP53, HNF1A, , HSF1

Biological processes related to prostate adenocarcinoma according to GeneDecks:

(show top 50)    (show all 79)

id	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:006915	INF	SLC9A3R1, PEG3, NGF, CASP3, MAPK1, FAS
2	signal transduction	GO:007165	INF	FAS, ANXA1, MAPK10, MAPK1, IGFBP5, IGFBP2
3	response to drug	GO:042493	INF	ERBB3, , PTGS2, , TGFBR2, TGFB1
4	positive regulation of cell proliferation	GO:008284	INF	TGFB1, HCLS1, EGFR, EGF, EDNRA, KRAS
5	negative regulation of apoptotic process	GO:043066	INF	RELA, PIM1, PIK3CG, FGFR1, EGFR,
6	negative regulation of transcription from RNA polymerase II promoter	GO:000122	INF	MYC, PPARA, , ESR2, TP53, EDNRB
7	MAPK cascade	GO:000165	INF	, INS, MAPK1, , KRAS, MYC
8	protein autophosphorylation	GO:046777	INF	, FGFR1, KDR, PIM1, ATM, FGFR2
9	positive regulation of gene expression	GO:010628	INF	BRAF, VEGFA, , CD44, MET,
10	epithelial to mesenchymal transition	GO:001837	INF	HGF, , S100A4, CTNNB1, NOTCH1,
11	negative regulation of neuron apoptotic process	GO:043524	INF	SOD2, SOD1, TGFA, HIF1A, KRAS, NGF
12	heart development	GO:007507	INF	RAF1, PTEN, WT1, ATM, CASP3, GJA1
13	positive regulation of protein kinase B signaling cascade	GO:051897	INF	INS, NRG1, , IGF1, IGFBP5, PIK3CG
14	blood coagulation	GO:007596	INF	SOD1, , FYN, ITGA2B, ITGB1, RAF1
15	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	INF	ERBB3, PDGFA, , IGF1, FGFR1, INS
16	positive regulation of cell growth	GO:030307	INF	HPN, SPHK1, IL2, INS, BCL2, UCN
17	positive regulation of MAPK cascade	GO:043410	INF	AR, PDGFA, IGF1, IGFBP3, , ITGB1
18	negative regulation of transcription, DNA-dependent	GO:045892	INF	ARID4A, CDKN1B, BIRC5, JUN, ,
19	cell proliferation	GO:008283	INF	GRPR, NPY, AR, MET, , ERBB2
20	cell-cell signaling	GO:007267	INF	PDGFA, PTHLH, AIMP1, GJA1, CALCA, GNRH1
21	positive regulation of ERK1 and ERK2 cascade	GO:070374	INF	CD44, EDNRA, PDGFA, BRAF, , KDR
22	cellular response to growth factor stimulus	GO:071363	INF	MET, FYN, CAT, , NTRK1, RPS6KB1
23	positive regulation of protein phosphorylation	GO:001934	INF	ERBB2, ENG, , , TGFB1, VEGFA
24	positive regulation of mesenchymal cell proliferation	GO:002053	10.3	TGFBR2, PDGFA, CTNNB1, MYC, KDR, FGFR1
25	response to organic cyclic compound	GO:014070	9.9	ANXA1, ENO2, JUN, FGF10, CCND1, MET
26	platelet degranulation	GO:002576	9.4	TGFB1, PDGFA, ITGA2B, PROS1, VEGFA, IGF1
27	neuron apoptotic process	GO:051402	9.3	TP63, TP53, CASP3, FAS, ATM, BAX
28	positive regulation of epithelial cell proliferation	GO:050679	9.3	BMP6, NME1, TGFB1, CYP7B1, ERBB2, MYC
29	wound healing	GO:042060	9.3	NRG1, TGFA, PPARA, ERBB2, ERBB3, ENG
30	positive regulation of DNA replication	GO:045740	8.7	CALR, PDGFA, JUN, INS, FGF10, MET
31	inflammatory response	GO:006954	INF	SPHK1, NGF, , , TGFB1, RELA
32	positive regulation of fibroblast proliferation	GO:048146	INF	MYC, JUN, MIF, NGFR, IGF1, SPHK1
33	positive regulation of peptidyl-serine phosphorylation	GO:033138	INF	TGFB1, , MET, MIF, CD44, RAF1
34	positive regulation of MAP kinase activity	GO:043406	INF	VEGFA, FGFR1, , ERBB2, PDGFA, KRAS
35	anti-apoptosis	GO:006916	INF	ANXA1, IGF1, , GNRH1, HSPB1, SPHK1
36	epidermal growth factor receptor signaling pathway	GO:007173	INF	MAPK1, RAF1, , ADAM10, CDKN1B, ADAM17
37	platelet activation	GO:030168	INF	EGF, PECAM1, IGF1, TF, MAPK1, ITGA2B
38	positive regulation of transcription from RNA polymerase II promoter	GO:045944	INF	VEGFA, RB1, FGF10, , NEUROD1, RELA
39	phosphatidylinositol-mediated signaling	GO:048015	INF	PDPK1, RPS6KB1, NTRK1, ERBB2, , IGF1
40	positive regulation of transcription, DNA-dependent	GO:045893	INF	RELA, RB1, MYC, , , JUN
41	positive regulation of apoptotic process	GO:043065	INF	CTNNB1, FAS, IGFBP3, , SOD1,
42	negative regulation of cell proliferation	GO:008285	INF	JUN, AZGP1, RAF1, RARB, , CDKN1B
43	angiogenesis	GO:001525	INF	VEGFA, PIK3CG, PDGFA, EGF, HIF1A, TYMP
44	activation of MAPKK activity	GO:000186	INF	NTRK1, ADAM9, RAF1,
45	virus-host interaction	GO:019048	INF	FYN, CARM1, TGFB1, , BAX, MAPK1
46	release of cytochrome c from mitochondria	GO:001836	INF	SOD2, CASP3, JUN, , MYC, BCL2
47	nerve growth factor receptor signaling pathway	GO:048011	INF	RAF1, BRAF, RELA, KRAS, ADAM17, CDKN1B
48	positive regulation of cell migration	GO:030335	INF	KDR, , MIEN1, VEGFA, ITGB1, INS
49	protein phosphorylation	GO:006468	INF	FYN, BIRC5, RAF1, BRAF, PIM1, TGFB1
50	response to hypoxia	GO:001666	INF	RAF1, , TGFB1, HIF1A, EDNRA, PPARA

Molecular functions related to prostate adenocarcinoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:019899	INF	CTNNB1, PPARG, NOTCH1, NFKBIA, EGFR, HIF1A
2	growth factor activity	GO:008083	INF	AMH, NRG1, NGF, PDGFA, EGF, TYMP
3	protein binding	GO:005515	INF	ESR2, CTNND2, NTRK1, PPARG, PPARA, NR1H2
4	receptor binding	GO:005102	INF	HLA-G, TNC, , CTNND1, NRG1, CRH
5	protein homodimerization activity	GO:042803	INF	PTGS2, HLA-G, ERBB3, AIMP1, HNF1A, CARM1
6	sequence-specific DNA binding	GO:043565	INF	NR1H2, WT1, HIF1A, , , NKX2-1
7	protein phosphatase binding	GO:019903	INF	EGFR, CTNND1, CTNNB1, ERBB2, ,
8	protein kinase binding	GO:019901	INF	HSPB1, TP53, PTEN, , PDPK1, HIF1A
9	transcription factor binding	GO:008134	INF	SRY, CTNNB1, NFKBIA, HIF1A, , NEUROD1
10	hormone activity	GO:005179	9.1	RLN1, CRH, SST, PTHLH, CALCA, GNRH1
11	transcription regulatory region DNA binding	GO:044212	INF	PPARG, NFKB1, WT1, HIF1A, , NKX2-1
12	sequence-specific DNA binding transcription factor activity	GO:003700	INF	HCLS1, WT1, NFKB1, NOTCH1, PPARA, PPARG
13	identical protein binding	GO:042802	INF	ERBB2, FAS, FGFR1, MLL, ITGA2B, TP53
14	protein heterodimerization activity	GO:046982	INF	HNF1A, ERBB3, ERBB2, TP53, PDGFA, EGFR
15	cytokine activity	GO:005125	INF	IL2, GPI, AIMP1, , SPP1, NRG1